Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What is the half-life of Wellbutrin XL?Does advil's effectiveness change with alcohol?What evidence supports lipitor's impact on lipids and plate?Are generic lipitor's side effects similar?What patient populations were sapropterin studies focused on?
See the DrugPatentWatch profile for Praluent
Praluent Patent Expiration and Biosimilar Competition What's driving competition around Praluent's patent expiration? Praluent, a cholesterol-lowering medication developed by Sanofi and Regeneron, has been a prominent treatment option for patients with elevated LDL (bad) cholesterol at high risk of cardiovascular events [1]. With patent expiration looming, the scene is set for the entry of biosimilars, which could challenge Praluent's market share. When does the Praluent patent expire? According to the patent expiration timeline, the US patent for Praluent is set to expire in 2025 [2]. However, the expiration dates for similar patents in other countries may differ. Regulatory pathway for biosimilar approval The regulatory path for biosimilar approval typically involves demonstrating biosimilarity to the reference product (Praluent in this case) through studies comparing efficacy and safety, as well as demonstrating comparable quality and stability. Once approved by regulatory agencies like the FDA, biosimilars can enter the market. How will patients be impacted by the entry of biosimilars? Biosimilars are expected to offer cost savings for patients, which may improve access to treatment and reduce healthcare expenses. Additionally, more competition among manufacturers could lead to better product quality and more treatment options. However, patients may also experience disruptions in their treatment regimen due to changes in available products and pricing. What factors could influence the timing of biosimilar entry? The exact timing of biosimilar entry will depend on several factors, including the patent expiration dates for individual countries, the regulatory approval process, and any ongoing litigation. Companies challenging Praluent's patent are likely seeking to delay or restrict biosimilar entry [3]. Source [1] DrugPatentWatch.com (2024) - Praluent [2] Praluent patent timeline (Source: United States Patent and Trademark Office) [3] Patent challenges (Source: LexisNexis)
Other Questions About Praluent :